J Korean Med Sci.  2006 Aug;21(4):639-644. 10.3346/jkms.2006.21.4.639.

Comparison of Serum Beta 2-Microglobulin and 24 hour Urinary Creatinine Clearance as a Prognostic Factor in Multiple Myeloma

• Yun JP
• Suh C
• Lee E
• Chang JW
• Yang WS
• Park JS
• Park SK

• KMID: 2157814
• DOI: http://doi.org/10.3346/jkms.2006.21.4.639

Abstract

A new staging system for multiple myeloma (MM) has utilized serum concentrations of beta 2-microglobulin (S beta2 M) and albumin as important prognostic factors for survival. Since S beta2 M is an indicator of glomerular filtration rate, we compared the prognostic values of S beta2 M and 24-hr urinary creatinine clearance (Ccr) in patients with MM. We retrospectively reviewed the records of 170 MM patients from January 1996 to November 2003 whose 24-hr urinary Ccr was available at the time of diagnosis. We found that pretreatment S beta2 M was inversely related to Ccr (Spearman's correlation coefficient=-0.787). In univariate analysis, the hazard ratio (HR) of death was 1.043 (p<0.001) for S beta2 M and 0.985 (p<0.001) for Ccr. Multivariate analysis showed that S beta2 M (HR 1.030, p=0.010) and Ccr (HR 0.993, p=0.059) were significant prognostic factors in patients' survival. In conclusion, 24-hr urinary Ccr may be utilized for staging of patients with MM.

Keyword

Multiple Myeloma; beta 2-Microglobulin; Glomerular Filtration Rate

MeSH Terms

beta 2-Microglobulin/*blood
Survival Analysis
Retrospective Studies
Prognosis
Neoplasm Staging/methods
Multivariate Analysis
Multiple Myeloma/drug therapy/metabolism/*pathology
Creatinine/*urine

Figure

• 

  Fig. 1 Relationship of beta 2-microglobulin and 24 hr urinary creatinine clearance before chemotherapy.

• 

  Fig. 2 Survival curves according to DS stage (A) and SWOG stage (B) with serum beta 2-microglobulin and serum albumin.

• 

  Fig. 3 Survival curves according to new staging system with Ccr and serum albumin.

Reference

1. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975. 36:842–854.

2. Jacobson JL, Hussein MA, Barlogie B, Durie BG, Crowley JJ. Southwest Oncology Group. A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. Br J Haematol. 2003. 122:441–450.

3. Cuzick J, Cooper EH, MacLennan IC. The prognostic value of serum beta 2-microglobulin compared with other presentation features in myelomatosis. Br J Cancer. 1985. 52:1–6.

4. Alexanian R, Barlogie B, Fritsche H. Beta 2-microglobulin in multiple myeloma. Am J Hematol. 1985. 20:345–351.

5. Scarffe JH, Anderson H, Palmer MK, Crowther D. Prognostic significance of pretreatment serum beta 2-microglobulin levels in multiple myeloma. Eur J Cancer Clin Oncol. 1983. 19:1361–1364.

6. Bataille R, Grenier J, Sany J. Beta-2-microglobulin in myeloma: optimal use for staging, prognosis, and treatment; a prospective study of 160 patients. Blood. 1984. 63:468–476.

7. Cuzick J, De Stavola BL, Cooper EH, Chapman C, MacLennan IC. Long-term prognostic value of serum beta 2 microglobulin in myelomatosis. Br J Haematol. 1990. 75:506–510.

8. Donadio C, Lucchesi A, Ardini M, Giordani R. Cystatin C, beta 2-microglobulin, and retinol-binding protein as indicators of glomerular filtration rate: comparison with plasma creatinine. J Pharm Biomed Anal. 2001. 24:835–842.

9. Jovanovic D, Krstivojevic P, Obradovic I, Durdevic V, Dukanovic L. Serum cystatin C and beta 2 microglobulin as markers of glomerular filtration rate. Ren Fail. 2003. 25:123–133.

10. Bianchi C, Donadio C, Tramonti G, Consani C, Lorusso P, Rossi G. Reappraisal of serum beta2-microglobulin as marker of GFR. Ren Fail. 2001. 23:419–429.

11. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003. 121:749–757.

12. Facon T, Avet-Loiseau H, Guillerm G, Moreau P, Genevieve F, Zandecki M, Lai JL, Leleu X, Jouet JP, Bauters F, Harousseau JL, Bataille R, Mary JY. Intergroupe Francophone du Myelome. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood. 2001. 97:1566–1571.

13. Greipp PR, Lust JA, O'Fallon WM, Katzmann JA, Witzig TE, Kyle RA. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood. 1993. 81:3382–3387.